ORBACTIV (oritavancin), antibiotic of the glycopeptide class

• ORBACTIV has Marketing Authorisation in the treatment of acute bacterial infections of the skin and soft tissues in adults.
• It does not provide any therapeutic benefit by comparison with vancomycin, since:

-       its in-vitro activity profile, efficacy and safety are comparable to that of vancomycin;

-       and there is insufficient documentation of clinical efficacy and safety in severe skin infections and/or skin infections caused by multidrug-resistant bacteria.

• It can be proposed only in situations where a glycopeptide is formally indicated and only in adult patients with infections of a certain severity for which a staphylococcal aetiology is proven or suspected and where resistance to methicillin is proven or strongly suspected.
• Given the characteristics of the product (long half-life) and current uncertainties about its clinical efficacy and safety in severe skin infections and/or skin infections caused by multidrug-resistant bacteria, the therapeutic decision must be made in consultation with an antibiotics expert.